|Mode of transmission||Faecal–oral route through close personal contact and fomites.|
|Incubation period||1–3 days.|
|Period of communicability||Immediately before, and up to 1–2 weeks after, the onset of symptoms.|
|Burden of disease||All children during infancy or early childhood. Severe disease occurs most often in children aged 3 months to 2 years.|
|Funded vaccine||RV5 (RotaTeq), a live attenuated, orally administered, pentavalent vaccine.|
|Funded immunisation indications and schedule||Infants at ages 6 weeks, 3 and 5 months. |
For catch-up schedules, the first dose should be given before age 15 weeks and the third dose should be given by age 8 months and 0 days.
|Vaccine efficacy/effectiveness||High effectiveness against severe rotavirus diarrhoea; some evidence for efficacy against all cause diarrhoea and for herd protection.|
|Contraindications||Acute or moderate gastroenteritis. |
With conditions that predispose the infant to intussusception.
Severe combined immune deficiency.
|Adverse events to vaccine||Potentially a very small risk for intussusception; the benefits of immunisation outweigh this potential risk.|